Comparing a new radiation therapy and long-acting medication for neuroendocrine tumors
Treatments studied
Part of Cancer clinical trials.
This phase 3 trial tests a radioactive drug (177Lu-DOTATATE) against a long-acting medication (Octreotide LAR) for people with advanced neuroendocrine tumors (NETs) that have grown despite standard treatment. The study aims to see which treatment works better and is safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of neuroendocrine tumor (G1 or G2, called GEP-NET) that can't be removed by surgery and has spread or is advanced.
- Your tumor showed up on a special PET scan (using gallium-68) meaning it has somatostatin receptors.
- You have at least one tumor that can be measured on imaging.
- You are 18 or older, with good organ function (kidneys, liver, bone marrow, heart).
- You have not had certain prior treatments: PRRT (peptide receptor radionuclide therapy), high-dose Octreotide LAR within 12 weeks, or other cancer treatments within 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, Ac-225 DOTATATE, in people with a type of gut or pancreas tumor (GEP-NET) that has specific proteins (SSTR) on its surface. The goal is to see if it is safe and helps shrink or slow the tumor.
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
This trial tests whether a radioactive drug called Lu177-Dotatate (PRRT) works better than usual care for people with slow-growing, advanced midgut neuroendocrine tumors (NETs). It may help shrink or slow the growth of tumors when you also get somatostatin analog therapy.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests whether repeating a targeted radioactive treatment (177Lu-DOTATATE) works better than standard options in people with metastatic gastroenteropancreatic neuroendocrine tumors. It may help by controlling tumor growth after the first round of this therapy stops working.
This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.
Hear when a new NETS Ga68 Lu177 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.